C

Cellectis SA

D
CLLS
USD
-0.02
(-1.1429%)
Market Closed
1,020.00
Volume
-0.95091
EPS
-
Div Yield
-1.411862
P/E
173,161,988.55
Market Cap
Today
-1.1429%
1 Week
-3.889%
1 Month
-12.361%
6 Months
-44.373%
12 Months
-27.311%
Year To Date
-43.092%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
B
BLUE
-0.0729
(-16.2614%)
USD
GILD
GILD
6.23
(6.7946%)
USD
E
EDIT
-0.11
(-3.3537%)
USD
C
CRSP
1.04
(2.0444%)
USD
B
BEAM
-0.53
(-1.991%)
USD
VRTX
VRTX
9.22
(1.869%)
USD
F
FATE
-0.24
(-8.6022%)
USD
A
ALLO
0.205
(6.8447%)
USD
N
NTLA
0.31
(1.9745%)
USD

Title:
Cellectis SA

Sector:
Healthcare
Industry:
Biotechnology
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
Do you need help or have a question?
Contact Us